Your browser doesn't support javascript.
loading
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial.
Al-Sawaf, Othman; Zhang, Can; Tandon, Maneesh; Sinha, Arijit; Fink, Anna-Maria; Robrecht, Sandra; Samoylova, Olga; Liberati, Anna M; Pinilla-Ibarz, Javier; Opat, Stephen; Sivcheva, Liliya; Le Dû, Katell; Fogliatto, Laura M; Niemann, Carsten U; Weinkove, Robert; Robinson, Sue; Kipps, Thomas J; Tausch, Eugen; Schary, William; Ritgen, Matthias; Wendtner, Clemens-Martin; Kreuzer, Karl-Anton; Eichhorst, Barbara; Stilgenbauer, Stephan; Hallek, Michael; Fischer, Kirsten.
Afiliação
  • Al-Sawaf O; Department I of Internal Medicine and Center of Integrated Oncology Cologne Aachen Cologne Bonn Duesseldorf, German CLL Study Group, University Hospital, University of Cologne, Germany.
  • Zhang C; Department I of Internal Medicine and Center of Integrated Oncology Cologne Aachen Cologne Bonn Duesseldorf, German CLL Study Group, University Hospital, University of Cologne, Germany.
  • Tandon M; Roche Products Limited, Welwyn Garden City, UK.
  • Sinha A; Roche Products Limited, Welwyn Garden City, UK.
  • Fink AM; Department I of Internal Medicine and Center of Integrated Oncology Cologne Aachen Cologne Bonn Duesseldorf, German CLL Study Group, University Hospital, University of Cologne, Germany.
  • Robrecht S; Department I of Internal Medicine and Center of Integrated Oncology Cologne Aachen Cologne Bonn Duesseldorf, German CLL Study Group, University Hospital, University of Cologne, Germany.
  • Samoylova O; Regional Clinical Hospital NA Semashko, Nizhny Novgorod, Russia.
  • Liberati AM; Division of Onco-Hematology, Santa Maria Terni Hospital, University of Perugia, Perugia, Italy.
  • Pinilla-Ibarz J; Department of Malignant Hematology, H Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
  • Opat S; Haematology Department, School of Clinical Sciences at Monash Health, Monash University, VIC, Australia.
  • Sivcheva L; First Internal Department, MHAT Hristo Botev, AD, Vratsa, Bulgaria.
  • Le Dû K; Hematology Department, Clinique Le Mans, France.
  • Fogliatto LM; Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil.
  • Niemann CU; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
  • Weinkove R; Wellington Blood and Cancer Centre, Capital and Coast District Health Board and Malaghan Institute of Medical Research, Wellington, New Zealand.
  • Robinson S; Queen Elizabeth II Health Science Center, Halifax, NS, Canada.
  • Kipps TJ; Moores Cancer Center, University of California San Diego, San Diego, CA, USA.
  • Tausch E; Department III of Internal Medicine, Ulm University, Ulm, Germany.
  • Schary W; AbbVie, North Chicago, IL, USA.
  • Ritgen M; Department II of Internal Medicine, Campus Kiel, University of Schleswig-Holstein, Kiel, Germany.
  • Wendtner CM; Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, Klinikum Schwabing, Munich, Germany.
  • Kreuzer KA; Department I of Internal Medicine and Center of Integrated Oncology Cologne Aachen Cologne Bonn Duesseldorf, German CLL Study Group, University Hospital, University of Cologne, Germany.
  • Eichhorst B; Department I of Internal Medicine and Center of Integrated Oncology Cologne Aachen Cologne Bonn Duesseldorf, German CLL Study Group, University Hospital, University of Cologne, Germany.
  • Stilgenbauer S; Department III of Internal Medicine, Ulm University, Ulm, Germany.
  • Hallek M; Department I of Internal Medicine and Center of Integrated Oncology Cologne Aachen Cologne Bonn Duesseldorf, German CLL Study Group, University Hospital, University of Cologne, Germany. Electronic address: michael.hallek@uk-koeln.de.
  • Fischer K; Department I of Internal Medicine and Center of Integrated Oncology Cologne Aachen Cologne Bonn Duesseldorf, German CLL Study Group, University Hospital, University of Cologne, Germany.
Lancet Oncol ; 21(9): 1188-1200, 2020 09.
Article em En | MEDLINE | ID: mdl-32888452
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Sulfonamidas / Leucemia Linfocítica Crônica de Células B / Clorambucila / Compostos Bicíclicos Heterocíclicos com Pontes / Anticorpos Monoclonais Humanizados Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Sulfonamidas / Leucemia Linfocítica Crônica de Células B / Clorambucila / Compostos Bicíclicos Heterocíclicos com Pontes / Anticorpos Monoclonais Humanizados Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article